Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C11H13N3O |
| Molecular Weight | 203.2404 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=NC(C)=CC=C1CN2CC2C#N
InChI
InChIKey=KOYMTVWMCXDJNV-UHFFFAOYSA-N
InChI=1S/C11H13N3O/c1-8-3-4-9(11(13-8)15-2)6-14-7-10(14)5-12/h3-4,10H,6-7H2,1-2H3
| Molecular Formula | C11H13N3O |
| Molecular Weight | 203.2404 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Ciamexon is an aziridine derivative with potent immuno-modulating activity developed by German pharmaceutical company Boehringer Mannheim G.m.b.H. for autoimmune diseases treatment. Ciamexon shows promising effects in experimental models of rheumatoid arthritis, diabetes, and obesity without toxic side effects. In animal studies, Ciamexon inhibits the proliferation of autoreactive lymphocytes dose-dependently, without affecting the reaction against foreign antigens. Clinical efficacy evaluation of the Ciamexon in patients with rheumatoid arthritis shows significant, dose-dependent improvement in both the clinical and the biochemical disease activity indexes. The major adverse effects of Ciamexon were hepatotoxicity, diarrhea, and rash.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2189417
400 mg/day of ciamexon for 6 mounths
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:31:01 GMT 2025
by
admin
on
Mon Mar 31 18:31:01 GMT 2025
|
| Record UNII |
325PG708LF
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C308
Created by
admin on Mon Mar 31 18:31:01 GMT 2025 , Edited by admin on Mon Mar 31 18:31:01 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000081899
Created by
admin on Mon Mar 31 18:31:01 GMT 2025 , Edited by admin on Mon Mar 31 18:31:01 GMT 2025
|
PRIMARY | |||
|
C76067
Created by
admin on Mon Mar 31 18:31:01 GMT 2025 , Edited by admin on Mon Mar 31 18:31:01 GMT 2025
|
PRIMARY | |||
|
5588
Created by
admin on Mon Mar 31 18:31:01 GMT 2025 , Edited by admin on Mon Mar 31 18:31:01 GMT 2025
|
PRIMARY | |||
|
71759
Created by
admin on Mon Mar 31 18:31:01 GMT 2025 , Edited by admin on Mon Mar 31 18:31:01 GMT 2025
|
PRIMARY | |||
|
75985-31-8
Created by
admin on Mon Mar 31 18:31:01 GMT 2025 , Edited by admin on Mon Mar 31 18:31:01 GMT 2025
|
PRIMARY | |||
|
325PG708LF
Created by
admin on Mon Mar 31 18:31:01 GMT 2025 , Edited by admin on Mon Mar 31 18:31:01 GMT 2025
|
PRIMARY | |||
|
C035520
Created by
admin on Mon Mar 31 18:31:01 GMT 2025 , Edited by admin on Mon Mar 31 18:31:01 GMT 2025
|
PRIMARY | |||
|
SUB06224MIG
Created by
admin on Mon Mar 31 18:31:01 GMT 2025 , Edited by admin on Mon Mar 31 18:31:01 GMT 2025
|
PRIMARY | |||
|
CHEMBL2104100
Created by
admin on Mon Mar 31 18:31:01 GMT 2025 , Edited by admin on Mon Mar 31 18:31:01 GMT 2025
|
PRIMARY | |||
|
DTXSID40868388
Created by
admin on Mon Mar 31 18:31:01 GMT 2025 , Edited by admin on Mon Mar 31 18:31:01 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE |
|
||
|
|
ENANTIOMER -> RACEMATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|